Dynamics of Oxidant-antioxidant System in Patients with Multidrug-resistant Tuberculosis Receiving Anti-mycobacterial Therapy

Dmytro O Butov1*, Michael M Kuzhko1, Irina M Kuznetsova2, Olena O Grinishina3, Olga A Maksimenko4, Tatjana S Butova1 and Irina M Kalmukova5

1Kharkiv National Medical University, Kharkiv, Ukraine
2F.G. Yanovsky National Institute of Physiatry & Pulmonology, National Academy of Medical Sciences, Kiev, Ukraine
3Regional TB Hospital № 1, Kharkiv, Ukraine
4Regional TB Dispensary № 3, Zmeyev, Ukraine
5Regional TB Hospital № 1, Kharkiv, Ukraine

Abstract
The changes in oxidant-antioxidant system were evaluated in serum samples of 140 patients with pulmonary tuberculosis, comprising those with multidrug-resistant TB (MDR-TB) and without MDR-TB and 30 healthy donors. The select parameters of Antioxidant System (AOS) including levels of thiol (–SH) groups, total antioxidant activity, glutathione peroxidase and glutathione reductase, were measured by spectrophotometry. At treatment initiation AOS and LPO values of TB patients were significantly lower or higher in comparison with healthy donors. After the two months of chemotherapy there was a significant increase of AOS and decrease in LPO values in TB patients. In patients with MDR-TB and relapsed pulmonary TB was noticed more pronounced authentic changes of pro-oxidant-antioxidant system in the blood of the comparison is not MDR TB and newly diagnosed pulmonary tuberculosis as for the standard anti-tuberculosis therapy since two months after treatment.

Keywords: Tuberculosis; Multidrug-resistant tuberculosis; Relapsed tuberculosis; Newly diagnosed pulmonary tuberculosis; Anti-tuberculosis therapy; Peroxide oxidation of lipids; Antioxidant system

Introduction
Tuberculosis (TB) remains the global problem of mankind with 8.8 million new cases of TB diagnosed each year and 1.4 million people dying from the disease [1,2]. The emergence of Multi-Drug-Resistant (MDR) and extensively drug-resistant TB threatens disease control efforts throughout the world [3,4]. About 50 million people are estimated to be infected with resistant strains of Mycobacterium tuberculosis [5].

In the last decade the Ukraine experienced marked increase in the proportion of TB strains resistant to one or more anti-mycobacterial drugs, causing reduced effectiveness of standard chemotherapy [6,7]. As a result the frequency of Relapsed or Recurrent Pulmonary Tuberculosis (RPTB) becomes higher [8]. The success of treating relapsed tuberculosis remains low resulting in higher rate of transition to chronic disease and increased mortality [9,10]. One of reasons for relapse include disorders in oxidant-antioxidant system, which affect the proper immune surveillance and exaggerates destructive inflammatory process underlying the variety of pathological changes [11,12]. Several studies have implicated local and systemic intensification of pro-oxidant-antioxidant system in various forms of pulmonary tuberculosis [13-15].

Clinical manifestations of TB, especially its progression and outcome, are closely associated with nonspecific metabolic perturbations in patients. TB is characterized by the activation of lipid peroxidation (LPO), reduced activity of Antioxidant System (AOS) and other related changes. These processes can play a significant role in elimination of Mycobacterium tuberculosis, but the imbalance in these processes can also causes damage to the healthy lung tissue and enhancement of inflammatory process [16-19].

One of the basic mechanisms that regulate the stability and permeability of cell membranes are LPO and AOS [16,20]. Normally the LPO, i.e., the formation of reactive oxygen species, is counterbalanced by AOS. Our study was aimed to uncover changes of pro-oxidant-antioxidant system in patients with various forms of RPTB, including those with MDR-TB. We have examined the dynamics of oxidant-antioxidant system in TB patients who were receiving anti-mycobacterial therapy.

Materials and Methods
We have followed 140 patients, aged 20 to 70 years, divided into three groups: the 1st group had 74 patients with MDR-TB; the 2nd group consisted of 66 patients who had pulmonary TB without MDR; and the 3rd group consisted of 30 healthy donors. The 1st group was further divided into two subgroups: 1A, which had 41 patients with RPTB with MDR-TB, 1B – had 33 patients with newly diagnosed pulmonary tuberculosis (NDPTB) with MDR-TB. The 2nd group which had patients without MDR-TB was also divided into subgroups: 2A, consisting of 15 patients with RPTB; 2B with 51 patients with NDPTB. All patients had infiltrating pulmonary TB and were receiving standard chemotherapy consisting of daily doses of: isoniazid (0.3 g); rifampicin (0.6 g); pyrazinamide (2.0 g); ethambutol (1.2 g); and/or streptomycin (1.0 g). Patients were recruited at the Regional TB Hospital № 1 and Regional TB Dispensary № 1. Both in Kharkiv; Regional TB Dispensary № 3 in Zmeev and Regional TB Dispensary № 4 in Izium, both in Kharkiv region.

Select parameters of LPO and AOS activities were evaluated

*Corresponding author: Dmytro O Butov, Kharkiv National Medical University, Kharkiv, Ukraine, E-mail: dddimad@yandex.ua

Received October 16, 2013; Accepted December 17, 2013; Published December 19, 2013


Copyright: © 2013 Butov DO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
by spectrophotometry in serum samples collected between 8 and 9 am prior to treatment initiation and 2 months later. The following parameters of LPO were measured: the content of conjugated Trienoic Fatty Acids (TC) and Lipofuscin Pigments (LP). The activity of AOS was evaluated by measuring thiol SH-groups, Total Antioxidant Activity (TAA), Glutathione Peroxidase (GP) and Glutathione Reductase (GR).

Obtained values were analyzed by the Student t-test. The difference was considered statistically significant at P<0.05 [25].

Results

The patients with pulmonary TB exhibited significant perturbations in LPO and AOS activities as compared to healthy controls. The parameters of pro-oxidant system in TB patients, as shown in Table 1, namely the TC and LP levels, were significantly higher than in healthy donors (P<0.05). The AOS levels, i.e., GP, GR, TAA and SH-groups, as indicated in Table 2, were significant lower than in healthy donors (P<0.05). In general in patients with pulmonary tuberculosis GP and TAA baseline values were almost twice lower and the LP is twice higher than in healthy donors.

Two months after treatment initiation with standard chemotherapy a significant reversal in indices of LPO and AOS activities was observed (P<0.05). The levels of TC in LPO system in group 2 and 2B after two months became practically same as in healthy controls (P<0.05) confirming relative recovery of LPO. For the AOS the recovery was seen in GR and SH- levels other parameters were significantly different (P<0.05) from healthy donors, suggesting the failure to recover after two months. For example levels of SH- in group 2 and 2B were significantly higher than in healthy controls. The comparison of MDR-TB patients (group 1) with those without MDR-TB (group 2) suggests a significant difference (p<0.05) in terms of reduction of almost all indicators as resulting from 2 months of chemotherapy. A significant difference between groups 1 and 2 was seen between treatment and post-treatment times and the gap was significantly higher in group 1 than in group 2 (p<0.05). The AOS indices were significantly higher in group 2 than in group 1, both prior to treatment and after two months (p<0.05).

The comparison of patients with relapsed and newly diagnosed pulmonary tuberculosis indicates a significant reduction (p<0.05) in all parameters before the treatment and after two months. The indicators of lipid peroxidation were significantly higher in patients with relapsed TB (1A and 2A subgroups) than in patients NDPTB (subgroups 1B and 2B) at both time points (p<0.05). In regard to the AOS significantly lower indices were seen in patients with RTBL (1A and 2A subgroups) than in NDPTB (1B and 2B subgroups) before and after treatment (p<0.05). In addition, in patients with RPTB MDR-TB (subgroup 1A) the values were significantly lower than in RPTB without MDR-TB (subgroup 2A). In patients with NDPTB MDR-TB (subgroup 1B) the

<table>
<thead>
<tr>
<th>Groups and subgroups (n)</th>
<th>Trienoic conjugates, mmol/L</th>
<th>Lipofuscin pigments, μmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before Rx</td>
<td>After 2 months</td>
</tr>
<tr>
<td>1 (n=74)</td>
<td>12.93 ± 0.25**</td>
<td>9.05 ± 0.21**</td>
</tr>
<tr>
<td>1A (n=41)</td>
<td>13.66 ± 0.322**</td>
<td>9.59 ± 0.252**</td>
</tr>
<tr>
<td>1B (n=33)</td>
<td>12.03 ± 0.352**</td>
<td>8.38 ± 0.3122**</td>
</tr>
<tr>
<td>2 (n=66)</td>
<td>10.68 ± 0.24**</td>
<td>7.21 ± 0.212**</td>
</tr>
<tr>
<td>2A (n=15)</td>
<td>12.08 ± 0.532**</td>
<td>8.24 ± 0.352**</td>
</tr>
<tr>
<td>2B (n=51)</td>
<td>10.26 ± 0.24**</td>
<td>6.92 ± 0.242**</td>
</tr>
<tr>
<td>3 (n=30)</td>
<td>7.05 ± 0.22</td>
<td>0.85 ± 0.02</td>
</tr>
</tbody>
</table>

# - difference significant (p<0.001) when comparing between 1 and 2 group, © - difference was significantly (p<0.05) when compared with group 3, α - difference is not significant (p>0.05) when compared with group 3, * - difference is significantly (p<0.001) when compared to treatment and after 2 months between the group (subgroup), © - significant difference (p<0.05) when comparing between 1A and 1B subgroup, © - significant difference (p<0.05) when comparing between 2A and 2B subgroup, © - significant difference (p<0.001) when comparing between 1A and 2A subgroup, © - the difference is not significant (p>0.05) when comparing between 2A and 1B subgroup

Table 1: Parameters of lipid peroxidation in patients with pulmonary tuberculosis and healthy donors (M ± m).

<table>
<thead>
<tr>
<th>Groups and subgroups (n)</th>
<th>Glutathione peroxidase, s.u.</th>
<th>Glutathione reductase, s.u.</th>
<th>Total antioxidant activity, %</th>
<th>SH-groups, mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>to treatment</td>
<td>After two months</td>
<td>to treatment</td>
<td>After two months</td>
</tr>
<tr>
<td>1 (n=74)</td>
<td>3.416 ± 0.09225**</td>
<td>4.562 ± 0.12072**</td>
<td>134.7 ± 1.91122**</td>
<td>191 ± 5.1522**</td>
</tr>
<tr>
<td>1A (n=41)</td>
<td>3.139 ± 0.0994222**</td>
<td>4.216 ± 0.1218222**</td>
<td>130 ± 2.4782222**</td>
<td>176 ± 5.8622222**</td>
</tr>
<tr>
<td>1B (n=33)</td>
<td>3.762 ± 0.1482222**</td>
<td>4.993 ± 0.2022222**</td>
<td>139.6 ± 2.7852222**</td>
<td>209.7 ± 7.9112222**</td>
</tr>
<tr>
<td>2 (n=66)</td>
<td>4.128 ± 0.1058222**</td>
<td>5.390 ± 0.1282222**</td>
<td>148.6 ± 3.3102222**</td>
<td>228.7 ± 5.4612222**</td>
</tr>
<tr>
<td>2A (n=15)</td>
<td>3.676 ± 0.16372222**</td>
<td>4.726 ± 0.16242222**</td>
<td>140.6 ± 1.62042222**</td>
<td>206.3 ± 9.5782222**</td>
</tr>
<tr>
<td>2B (n=51)</td>
<td>4.261 ± 0.12272222**</td>
<td>5.585 ± 0.14852222**</td>
<td>150.9 ± 4.10912222**</td>
<td>235.2 ± 6.2172222**</td>
</tr>
<tr>
<td>3 (n=30)</td>
<td>6.297 ± 0.19852222**</td>
<td>217.6 ± 5.9012222**</td>
<td>64.73 ± 1.1512222**</td>
<td>66.6 ± 0.25882222**</td>
</tr>
</tbody>
</table>

# - difference significant (p<0.01) when comparing between 1 and 2 group, © - difference was significantly (p<0.05) when compared with group 3, α - difference is not significant (p>0.05) when compared with group 3, * - difference was significantly (p<0.001) when compared to treatment and after 2 months between the group (subgroup), © - significant difference (p<0.05) when comparing between 1A and 1B subgroup, © - significant difference (p<0.01) when Comparing between 1B and 2B subgroup, © - significant difference (p<0.05) when comparing between 2A and 2B subgroup, · - significant difference (p<0.01) when comparing between 1A and 2A subgroup, · - the difference is not significant (p>0.05) when comparing between 2A and 1B subgroup

Table 2: Condition indicators antioxidant defense in patients with pulmonary tuberculosis and healthy donors (M ± m).
values were lower than in subgroup 2B patients, and lipid peroxidation indices in patients with NDPTB without MDR-TB were also lower than in patients 1B subgroup (p <0.05). The indicators of lipid peroxidation in subgroup 1A were significantly higher than in subgroup 2A (p<0.05) at both time points.

Conclusion

We have conducted the measurements of antioxidant enzyme activity and lipid peroxidation parameters in 140 TB patients prior to and after two months on standard TB chemotherapy. In patients with pulmonary tuberculosis marked changes in the prooxidant-antioxidant system were observed as manifested by accumulation in the blood of LPO markers (TC and LP) and decreased function of the antioxidant system. Our data shows more pronounced disturbance in LPO and AOS in patients with relapsed and MDR-TB as compared to those who had newly diagnosed TB or were without MDR-TB. At the end of two months of standard anti-tuberculosis therapy we have observed relative normalization of parameters of LPO and AOS.

Increased activity of lipid peroxidation and decreased performance of AOS in patients with pulmonary tuberculosis provides a rationale to use in addition to standard TB therapy the antioxidant and membrane stabilizing interventions, especially in patients with relapsed MDR-TB.

Acknowledgements

We thank all volunteers who participated in this study. The wholehearted support of clinicians, nurses and lab personnel who contributed their effort made this study possible. Our gratitude is expressed to many experts in TB and support of clinicians, nurses and lab personnel who contributed their effort in chronic bronchitis and ischemic heart disease. Bull Exp Biol 10: 452-454.

References


Submit your next manuscript and get advantages of OMICS

Group submissions

Unique features:

• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:

• 300 Open Access Journals
• 25,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (indexed), Sopus, BMJCD, Index Copernicus and Google Scholar etc.
• Sharing Options Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission/